<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68185">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218203</url>
  </required_header>
  <id_info>
    <org_study_id>RO1NS41503-2</org_study_id>
    <nct_id>NCT02218203</nct_id>
  </id_info>
  <brief_title>Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial</brief_title>
  <official_title>Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled, double-blind 4x4 factorial crossover clinical trial was
      part of a larger NIH-funded study to evaluate the analgesic efficacy of multiple
      dose-combinations of chronic oral (PO)dextromethorphan and intravenous (IV) lidocaine in
      central neuropathic pain following spinal cord injury.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Reduction in Peak Pain Intensity</measure>
    <time_frame>30 minutes post-infusion (Cmax)</time_frame>
    <description>Primary outcome was mean pain intensity at Cmax (transformed Gracely Scale).</description>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Central Neuropathic Pain</condition>
  <condition>Allodynia</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Placebo- 0mg/kg Lido</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with 0mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 1mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in combination with 1mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 2mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in combination with 2mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - 4mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in combination with 4mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose dextromethorphan in combination with 0mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose dextromethorphan in combination with 1mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose dextromethorphan in combination with 2mg/kg LBM lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose dextromethorphan in combination with 4mg/kg LBM lidocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject</description>
    <arm_group_label>Low Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 4mg/kg Lido</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)</description>
    <arm_group_label>Placebo - 1mg/kg Lido</arm_group_label>
    <arm_group_label>Placebo - 2mg/kg Lido</arm_group_label>
    <arm_group_label>Placebo - 4mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 4mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 1mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 2mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 4mg/kg Lido</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Dextromethorphan)</intervention_name>
    <description>0mg Dextromethorphan</description>
    <arm_group_label>Placebo- 0mg/kg Lido</arm_group_label>
    <arm_group_label>Placebo - 1mg/kg Lido</arm_group_label>
    <arm_group_label>Placebo - 2mg/kg Lido</arm_group_label>
    <arm_group_label>Placebo - 4mg/kg Lido</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Lidocaine)</intervention_name>
    <description>0mg/kg LBM Lidocaine</description>
    <arm_group_label>Placebo- 0mg/kg Lido</arm_group_label>
    <arm_group_label>Low Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_label>Medium Dose Dex - 0mg/kg Lido</arm_group_label>
    <arm_group_label>High Dose Dex - 0mg/kg Lido</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female adults, age 18 to 70 with central neuropathic pain for a
             minimum of 3 months following SCI as confirmed by neurologic evaluation, with an
             average pain intensity score of at least moderate over at least 50% of the day for
             the 7 days prior to the screening visit and over the 7 days prior to starting study
             medication.

          2. Subjects used no medication or a stabilized medication regimen for chronic and
             well-controlled medical conditions

          3. Serum laboratory examination obtained at study entry:

               -  Liver function tests (albumin within 20% of normal, SGOT/SGPT within 50% of
                  normal).

               -  For women of childbearing age: negative serum beta HCG.

          4. Postmenopausal women, or be physically incapable of childbearing, or be practicing an
             acceptable method of birth control.

          5. Normal cognitive function.

          6. Normal communicative ability (English).

          7. Ability to demonstrate competence in recording five times daily in pain diary for 1
             week (with 100% compliance), and in completing required questionnaires.

          8. Signed informed consent.

        Exclusion Criteria:

          1. Pregnancy or breast-feeding.

          2. Renal or hepatic dysfunction.

          3. Significant cardiac disease (e.g. MI within 1 year).

          4. Signs or symptoms of central neurological disorder, excluding SCI.

          5. Severe psychological disorder requiring treatment.

          6. Concurrent use of monoamine oxidase inhibitors within 2 weeks prior to study entry.

          7. Use of known CYP2D6 (but not CYP3A4) inhibitors or inducers.

          8. History of hypersensitivity or intolerance to dextromethorphan or lidocaine.

          9. Chronic substance abuse, including alcohol.

         10. Participation in a study of an investigational drug or device within 30 days prior to
             screening for this study.

         11. Poor metabolizer of P450 2D6 substrates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine N. Sang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Pain Research, Brigham and Women's Hospital (Disclosure: Patent)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Translational Pain Research, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.paintrials.org</url>
    <description>Translational Pain Research, Brigham and Women's Hospital</description>
  </link>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 15, 2014</lastchanged_date>
  <firstreceived_date>August 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Christine N. Sang, MD, MPH</investigator_full_name>
    <investigator_title>Director, Translational Pain Research</investigator_title>
  </responsible_party>
  <keyword>chronic pain</keyword>
  <keyword>central neuropathic pain</keyword>
  <keyword>spinal cord injury</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>lidocaine</keyword>
  <keyword>combination therapy</keyword>
  <keyword>analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
